BRIEF

on Medicure, Inc. (NASDAQ:MCUJF)

Medicure's Q3 2026 Financial Results Show Revenue Decline

Medicure Inc. reported its financial results for the quarter ended September 30, 2026. The company's net revenue reached $7.9 million, slightly down from $8.2 million in Q3 2025. ZYPITAMAG® sales remained stable at $1.7 million, with AGGRASTAT® sales dipping to $979,000 from $1 million in the same quarter the previous year.

The pharmacy business segment, including Marley Drug and two acquired pharmacies, posted revenues of $6.1 million, a decrease from $6.4 million in Q3 2025. Despite a $676,000 investment in R&D, which is less than the $717,000 from the previous year, the adjusted EBITDA showed a deeper loss at negative $820,000 compared to negative $597,000 in Q3 2025. The net loss was $1.3 million, consistent with last year's $1.4 million loss for the same period.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Medicure, Inc. news